Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 11/20 | 1.00 |
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060925 | 1.00 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL28465778 | 0.90 | HTR2A (0.81) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL11821618 | 0.85 | HTR2A (0.74) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL8492268 | 0.83 | HTR2A (0.76) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL8316644 | 0.82 | HTR2C (0.69) | HTR2AKCNH2HTR2C | |
| SCHEMBL8525019 | 0.82 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL7959758 | 0.80 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL22588189 | 0.79 | HTR2A (0.65) | HTR2AKCNH2HTR2C | |
| SCHEMBL31285825 | 0.79 | HTR2A (0.65) | HTR2AKCNH2HTR2C | |
| SCHEMBL7967298 | 0.78 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| WO-2007127635-A2 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-6316468-B1 | Phenylindole derivatives as 5-HT2A receptor antagonists | MERCK SHARP & DOHME LTD. | 2001-11-13 | — | — | US | disclosed |
| WO-1999011641-A1 | PHENYLINDOLE DERIVATIVES AS 5-HT2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1999-03-11 | — | — | WO | disclosed |
| EP-0224919-A2 | New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | HTR2A 1280/4885KCNH2 562/4885HTR2C 1590/4885 |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | HTR2A 1280/4885KCNH2 562/4885HTR2C 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.